Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects

Trial Profile

Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Cenerimod (Primary) ; Atenolol; Diltiazem
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2016 Status changed from suspended to discontinued.
    • 12 Aug 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 27 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top